This factor has been linked to better prognoses for patients with ICC [12, 20] and has been found to predict improved immunotherapeutic response for ICC and other solid tumours, such as hepatocellular carcinoma and melanoma, regardless of PD-L1 expression and CD8+ T-cell density [12–16]. This evidence concerns the gene CD8A and melanoma.